{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:24:00Z","timestamp":1792596240966,"version":"4.5.0"},"reference-count":46,"publisher":"National Academy of Sciences","issue":"47","license":[{"start":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T00:00:00Z","timestamp":1509926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2017,11,21]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>We recently reported that activin type II receptors (ActRIIs) blockade using bimagrumab could positively impact muscle wasting in mice and humans. However, the specific role of each individual ActRII at regulating adult muscle mass had not been clarified. Here, we highlight the importance of concomitant neutralization of both ActRIIs in controlling muscle mass. Through comparison with single specificity antibodies, we uncover unique features related to bimagrumab and its neutralizing interactions with both ActRIIA and ActRIIB at the structural and cellular levels and in vivo in adult mice. The need for simultaneous engagement and neutralization of both ActRIIs to generate a strong skeletal muscle response confers unique therapeutic potential to bimagrumab, in the context of muscle wasting conditions.<\/jats:p>","DOI":"10.1073\/pnas.1707925114","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T15:21:02Z","timestamp":1509981662000},"page":"12448-12453","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":135,"title":["Blockade of activin type II receptors with a dual anti-ActRIIA\/IIB antibody is critical to promote maximal skeletal muscle hypertrophy"],"prefix":"10.1073","volume":"114","author":[{"given":"Frederic","family":"Morvan","sequence":"first","affiliation":[{"name":"MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Rondeau","sequence":"additional","affiliation":[{"name":"Chemical Biology and Therapeutics, Structural Biophysics Group, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zou","sequence":"additional","affiliation":[{"name":"Chemical Biology and Therapeutics, Structural Biophysics Group, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Minetti","sequence":"additional","affiliation":[{"name":"MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Scheufler","sequence":"additional","affiliation":[{"name":"Chemical Biology and Therapeutics, Structural Biophysics Group, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Scharenberg","sequence":"additional","affiliation":[{"name":"Novartis Biologics Center, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Jacobi","sequence":"additional","affiliation":[{"name":"MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Brebbia","sequence":"additional","affiliation":[{"name":"MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Ritter","sequence":"additional","affiliation":[{"name":"MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauthier","family":"Toussaint","sequence":"additional","affiliation":[{"name":"MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Koelbing","sequence":"additional","affiliation":[{"name":"MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leber","sequence":"additional","affiliation":[{"name":"Novartis Biologics Center, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Schilb","sequence":"additional","affiliation":[{"name":"MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Witte","sequence":"additional","affiliation":[{"name":"MorphoSys AG, 82152 Martinsried\/Planegg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Chemical Biology and Therapeutics, Structural Biophysics Group, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Koch","sequence":"additional","affiliation":[{"name":"Chemical Biology and Therapeutics, Structural Biophysics Group, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Geisse","sequence":"additional","affiliation":[{"name":"Novartis Biologics Center, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Glass","sequence":"additional","affiliation":[{"name":"Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Lach-Trifilieff","sequence":"additional","affiliation":[{"name":"MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2017,11,6]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/10409238.2013.857291","article-title":"Signaling pathways controlling skeletal muscle mass","volume":"49","author":"Egerman MA","year":"2014","unstructured":"MA Egerman, DJ Glass, Signaling pathways controlling skeletal muscle mass. Crit Rev Biochem Mol Biol 49, 59\u201368 (2014).","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.biocel.2013.06.011","article-title":"Disuse-induced muscle wasting","volume":"45","author":"Bodine SC","year":"2013","unstructured":"SC Bodine, Disuse-induced muscle wasting. Int J Biochem Cell Biol 45, 2200\u20132208 (2013).","journal-title":"Int J Biochem Cell Biol"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1749-6632.2010.05809.x","article-title":"Recent advances in the biology and therapy of muscle wasting","volume":"1211","author":"Glass D","year":"2010","unstructured":"D Glass, R Roubenoff, Recent advances in the biology and therapy of muscle wasting. Ann N Y Acad Sci 1211, 25\u201336 (2010).","journal-title":"Ann N Y Acad Sci"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"i44","DOI":"10.1093\/fampra\/cmr063","article-title":"Sarcopenia in the elderly","volume":"29","author":"Morley JE","year":"2012","unstructured":"JE Morley, Sarcopenia in the elderly. Fam Pract 29, i44\u2013i48 (2012).","journal-title":"Fam Pract"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","article-title":"Myostatin\/activin pathway antagonism: Molecular basis and therapeutic potential","volume":"45","author":"Han HQ","year":"2013","unstructured":"HQ Han, X Zhou, WE Mitch, AL Goldberg, Myostatin\/activin pathway antagonism: Molecular basis and therapeutic potential. Int J Biochem Cell Biol 45, 2333\u20132347 (2013).","journal-title":"Int J Biochem Cell Biol"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1126\/science.1069525","article-title":"Induction of cachexia in mice by systemically administered myostatin","volume":"296","author":"Zimmers TA","year":"2002","unstructured":"TA Zimmers, , Induction of cachexia in mice by systemically administered myostatin. Science 296, 1486\u20131488 (2002).","journal-title":"Science"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member","volume":"387","author":"McPherron AC","year":"1997","unstructured":"AC McPherron, AM Lawler, SJ Lee, Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387, 83\u201390 (1997).","journal-title":"Nature"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"12457","DOI":"10.1073\/pnas.94.23.12457","article-title":"Double muscling in cattle due to mutations in the myostatin gene","volume":"94","author":"McPherron AC","year":"1997","unstructured":"AC McPherron, SJ Lee, Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 94, 12457\u201312461 (1997).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa040933","article-title":"Myostatin mutation associated with gross muscle hypertrophy in a child","volume":"350","author":"Schuelke M","year":"2004","unstructured":"M Schuelke, , Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350, 2682\u20132688 (2004).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1210\/me.2010-0127","article-title":"Regulation of muscle mass by follistatin and activins","volume":"24","author":"Lee SJ","year":"2010","unstructured":"SJ Lee, , Regulation of muscle mass by follistatin and activins. Mol Endocrinol 24, 1998\u20132008 (2010).","journal-title":"Mol Endocrinol"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"18117","DOI":"10.1073\/pnas.0505996102","article-title":"Regulation of muscle growth by multiple ligands signaling through activin type II receptors","volume":"102","author":"Lee SJ","year":"2005","unstructured":"SJ Lee, , Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 102, 18117\u201318122 (2005).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2044-5040-2-3","article-title":"TAK-1\/p38\/nNF\u03baB signaling inhibits myoblast differentiation by increasing levels of activin A","volume":"2","author":"Trendelenburg AU","year":"2012","unstructured":"AU Trendelenburg, A Meyer, C Jacobi, JN Feige, DJ Glass, TAK-1\/p38\/nNF\u03baB signaling inhibits myoblast differentiation by increasing levels of activin A. Skelet Muscle 2, 3 (2012).","journal-title":"Skelet Muscle"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1210\/me.2008-0290","article-title":"Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators","volume":"22","author":"Souza TA","year":"2008","unstructured":"TA Souza, , Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Mol Endocrinol 22, 2689\u20132702 (2008).","journal-title":"Mol Endocrinol"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-213X-9-24","article-title":"Redundancy of myostatin and growth\/differentiation factor 11 function","volume":"9","author":"McPherron AC","year":"2009","unstructured":"AC McPherron, TV Huynh, SJ Lee, Redundancy of myostatin and growth\/differentiation factor 11 function. BMC Dev Biol 9, 24 (2009).","journal-title":"BMC Dev Biol"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1126\/science.1251152","article-title":"Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle","volume":"344","author":"Sinha M","year":"2014","unstructured":"M Sinha, , Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science 344, 649\u2013652 (2014).","journal-title":"Science"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cmet.2015.05.010","article-title":"GDF11 increases with age and inhibits skeletal muscle regeneration","volume":"22","author":"Egerman MA","year":"2015","unstructured":"MA Egerman, , GDF11 increases with age and inhibits skeletal muscle regeneration. Cell Metab 22, 164\u2013174 (2015).","journal-title":"Cell Metab"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/acel.12475","article-title":"Lack of evidence for GDF11 as a rejuvenator of aged skeletal muscle satellite cells","volume":"15","author":"Hinken AC","year":"2016","unstructured":"AC Hinken, , Lack of evidence for GDF11 as a rejuvenator of aged skeletal muscle satellite cells. Aging Cell 15, 582\u2013584 (2016).","journal-title":"Aging Cell"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"15153","DOI":"10.1038\/ncomms15153","article-title":"Activin A more prominently regulates muscle mass in primates than does GDF8","volume":"8","author":"Latres E","year":"2017","unstructured":"E Latres, , Activin A more prominently regulates muscle mass in primates than does GDF8. Nat Commun 8, 15153 (2017).","journal-title":"Nat Commun"},{"key":"e_1_3_4_19_2","first-page":"E5266","article-title":"Specific targeting of TGF-\u03b2 family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease","volume":"114","author":"Chen JL","year":"2017","unstructured":"JL Chen, , Specific targeting of TGF-\u03b2 family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc Natl Acad Sci USA 114, E5266\u2013E5275 (2017).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1128\/MCB.23.20.7230-7242.2003","article-title":"Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis","volume":"23","author":"Rebbapragada A","year":"2003","unstructured":"A Rebbapragada, H Benchabane, JL Wrana, AJ Celeste, L Attisano, Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 23, 7230\u20137242 (2003).","journal-title":"Mol Cell Biol"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0006-291X(02)02953-4","article-title":"Inhibition of myostatin in adult mice increases skeletal muscle mass and strength","volume":"300","author":"Whittemore LA","year":"2003","unstructured":"LA Whittemore, , Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300, 965\u2013971 (2003).","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13395-015-0060-8","article-title":"Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice","volume":"5","author":"Latres E","year":"2015","unstructured":"E Latres, , Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet Muscle 5, 34 (2015).","journal-title":"Skelet Muscle"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","article-title":"Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial","volume":"3","author":"Becker C","year":"2015","unstructured":"C Becker, , Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol; STEADY Group 3, 948\u2013957 (2015).","journal-title":"Lancet Diabetes Endocrinol"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1096\/fj.04-2796com","article-title":"Myostatin propeptide-mediated amelioration of dystrophic pathophysiology","volume":"19","author":"Bogdanovich S","year":"2005","unstructured":"S Bogdanovich, KJ Perkins, TOB Krag, LA Whittemore, TS Khurana, Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 19, 543\u2013549 (2005).","journal-title":"FASEB J"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"e12707","DOI":"10.1371\/journal.pone.0012707","article-title":"Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition","volume":"5","author":"Goncalves MD","year":"2010","unstructured":"MD Goncalves, , Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition. PLoS One 5, e12707 (2010).","journal-title":"PLoS One"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou X","year":"2010","unstructured":"X Zhou, , Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531\u2013543 (2010).","journal-title":"Cell"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mus.23539","article-title":"A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers","volume":"47","author":"Attie KM","year":"2013","unstructured":"KM Attie, , A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve 47, 416\u2013423 (2013).","journal-title":"Muscle Nerve"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Lach-Trifilieff E","year":"2014","unstructured":"E Lach-Trifilieff, , An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol 34, 606\u2013618 (2014).","journal-title":"Mol Cell Biol"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13395-016-0098-2","article-title":"ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments","volume":"6","author":"Hatakeyama S","year":"2016","unstructured":"S Hatakeyama, , ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet Muscle 6, 26 (2016).","journal-title":"Skelet Muscle"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cyto.2014.06.017","article-title":"Regulation and actions of activin A and follistatin in myocardial ischaemia-reperfusion injury","volume":"69","author":"Chen Y","year":"2014","unstructured":"Y Chen, , Regulation and actions of activin A and follistatin in myocardial ischaemia-reperfusion injury. Cytokine 69, 255\u2013262 (2014).","journal-title":"Cytokine"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/4887","article-title":"Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase","volume":"6","author":"Greenwald J","year":"1999","unstructured":"J Greenwald, WH Fischer, WW Vale, S Choe, Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase. Nat Struct Biol 6, 18\u201322 (1999).","journal-title":"Nat Struct Biol"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.1073\/pnas.0602558103","article-title":"Structure of the ternary signaling complex of a TGF-beta superfamily member","volume":"103","author":"Allendorph GP","year":"2006","unstructured":"GP Allendorph, WW Vale, S Choe, Structure of the ternary signaling complex of a TGF-beta superfamily member. Proc Natl Acad Sci USA 103, 7643\u20137648 (2006).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1097-2765(03)00094-7","article-title":"The BMP7\/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly","volume":"11","author":"Greenwald J","year":"2003","unstructured":"J Greenwald, , The BMP7\/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol Cell 11, 605\u2013617 (2003).","journal-title":"Mol Cell"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6807-7-6","article-title":"A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor","volume":"7","author":"Weber D","year":"2007","unstructured":"D Weber, , A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor. BMC Struct Biol 7, 6 (2007).","journal-title":"BMC Struct Biol"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molcel.2004.07.011","article-title":"A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors","volume":"15","author":"Greenwald J","year":"2004","unstructured":"J Greenwald, , A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors. Mol Cell 15, 485\u2013489 (2004).","journal-title":"Mol Cell"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/emboj\/cdg156","article-title":"Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions","volume":"22","author":"Thompson TB","year":"2003","unstructured":"TB Thompson, TK Woodruff, TS Jardetzky, Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions. EMBO J 22, 1555\u20131566 (2003).","journal-title":"EMBO J"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12915-017-0350-1","article-title":"Structural basis for potency differences between GDF8 and GDF11","volume":"15","author":"Walker RG","year":"2017","unstructured":"RG Walker, , Structural basis for potency differences between GDF8 and GDF11. BMC Biol 15, 19 (2017).","journal-title":"BMC Biol"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.nmd.2014.06.281","article-title":"G.P.205","volume":"24","author":"Mulivor A","year":"2014","unstructured":"A Mulivor, , G.P.205. Neuromuscular Disord 24, 878 (2014).","journal-title":"Neuromuscular Disord"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial","volume":"55","author":"Campbell C","year":"2017","unstructured":"C Campbell, , Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve 55, 458\u2013464 (2017).","journal-title":"Muscle Nerve"},{"key":"e_1_3_4_40_2","article-title":"Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals","author":"Garito T","year":"2017","unstructured":"T Garito, , Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals. Diabetes Obes Metab, 2017).","journal-title":"Diabetes Obes Metab"},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jgs.14927","article-title":"Treatment of sarcopenia with bimagrumab: Results from a phase II, randomized, controlled, proof-of-concept study","volume":"65","author":"Rooks D","year":"2017","unstructured":"D Rooks, , Treatment of sarcopenia with bimagrumab: Results from a phase II, randomized, controlled, proof-of-concept study. J Am Geriatr Soc 65, 1988\u20131995 (2017).","journal-title":"J Am Geriatr Soc"},{"key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato AA","year":"2014","unstructured":"AA Amato, , Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 83, 2239\u20132246 (2014).","journal-title":"Neurology"},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1083\/jcb.201211134","article-title":"The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass","volume":"203","author":"Winbanks CE","year":"2013","unstructured":"CE Winbanks, , The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. J Cell Biol 203, 345\u2013357 (2013).","journal-title":"J Cell Biol"},{"key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/ng.2772","article-title":"BMP signaling controls muscle mass","volume":"45","author":"Sartori R","year":"2013","unstructured":"R Sartori, , BMP signaling controls muscle mass. Nat Genet 45, 1309\u20131318 (2013).","journal-title":"Nat Genet"},{"key":"e_1_3_4_45_2","first-page":"62","article-title":"A phase 2 randomized study investigating the efficacy and safety of myostatin antibody LY2495655 versus placebo in patients undergoing elective total hip arthroplasty","volume":"5","author":"Woodhouse L","year":"2016","unstructured":"L Woodhouse, , A phase 2 randomized study investigating the efficacy and safety of myostatin antibody LY2495655 versus placebo in patients undergoing elective total hip arthroplasty. J Frailty Aging; STUDY INVESTIGATORS 5, 62\u201370 (2016).","journal-title":"J Frailty Aging"},{"key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cmet.2016.05.023","article-title":"Quantification of GDF11 and myostatin in human aging and cardiovascular disease","volume":"23","author":"Schafer MJ","year":"2016","unstructured":"MJ Schafer, , Quantification of GDF11 and myostatin in human aging and cardiovascular disease. Cell Metab 23, 1207\u20131215 (2016).","journal-title":"Cell Metab"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1707925114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T12:27:06Z","timestamp":1654604826000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1707925114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,6]]},"references-count":46,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2017,11,21]]}},"alternative-id":["10.1073\/pnas.1707925114"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1707925114","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,6]]},"assertion":[{"value":"2017-11-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}